Catalysts for Sciegen Pharmaceuticals Inc
49 tracked
Apr 10, 2026
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Sciegen Pharmaceuticals Inc
→
Mar 31, 2026
approval
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approval
Sciegen Pharmaceuticals Inc
→
Mar 16, 2026
approval
DESOXIMETASONE — FDA approval
Sciegen Pharmaceuticals Inc
→
Mar 16, 2026
approval
DESOXIMETASONE — FDA approval
Sciegen Pharmaceuticals Inc
→
Feb 17, 2026
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Feb 17, 2026
approval
GABAPENTIN — FDA approval
Sciegen Pharmaceuticals Inc
→
Jan 22, 2026
approval
ATORVASTATIN CALCIUM — FDA approval
Sciegen Pharmaceuticals Inc
→
Nov 6, 2025
approval
BUPROPION HYDROCHLORIDE — FDA approval
Sciegen Pharmaceuticals Inc
→
Oct 28, 2025
approval
TICAGRELOR — FDA approval
Sciegen Pharmaceuticals Inc
→
Sep 19, 2025
approval
GABAPENTIN — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 31, 2024
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 31, 2024
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 31, 2024
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 31, 2024
approval
GABAPENTIN — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 31, 2024
approval
GABAPENTIN — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 31, 2024
approval
GABAPENTIN — FDA approval
Sciegen Pharmaceuticals Inc
→
May 7, 2024
approval
BUPROPION HYDROCHLORIDE — FDA approval
Sciegen Pharmaceuticals Inc
→
Apr 6, 2023
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Sciegen Pharmaceuticals Inc
→
Mar 8, 2023
approval
ATORVASTATIN CALCIUM — FDA approval
Sciegen Pharmaceuticals Inc
→
Oct 25, 2022
approval
ATORVASTATIN CALCIUM — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 13, 2021
approval
BUPROPION HYDROCHLORIDE — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 13, 2021
approval
BUPROPION HYDROCHLORIDE — FDA approval
Sciegen Pharmaceuticals Inc
→
Dec 13, 2021
approval
BUPROPION HYDROCHLORIDE — FDA approval
Sciegen Pharmaceuticals Inc
→
May 27, 2021
approval
ATORVASTATIN CALCIUM — FDA approval
Sciegen Pharmaceuticals Inc
→
May 27, 2021
approval
ATORVASTATIN CALCIUM — FDA approval
Sciegen Pharmaceuticals Inc
→
Sep 29, 2020
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Sep 29, 2020
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Sep 29, 2020
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Sep 29, 2020
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→
Sep 29, 2020
approval
RELGAABI (GABAPENTIN) — FDA approval
Sciegen Pharmaceuticals Inc
→